ATTACHMENT ASSEMBLY FOR GAS TURBINE NOZZLE AND METHOD OF ATTACHMENT, OF REMOVING AND INSTALLING

SURGICAL INSTRUMENT WITH TELESCOPIC FIXING

... 1. la présente invention concerne un tube de fixation (40) pour soutenir une tige mobile d'un outil (50) de dissection chirurgical, la fixation (40) comprenant un corps cylindrique (40) ayant une surface externe, une partie proximale (42) et définissant un passage interne pour recevoir au moins partiellement un outil (50) de dissection chirurgical, ladite surface externe définissant au moins une cannelure (44) s'étendant le long de ladite surface externe adjacente à ladite partie proximale (42).

PROCEEDED OF DEPOSIT BY ELECTROLYTIC WAY Of a COMPOSITE COATING HAS METAL MATRIX CONTAINING OF the PARTICLES, FOR the REPAIR Of a METAL PADDLE

Selon l'invention, on fournit une aube (120, 130) formant la cathode et présentant une surface à revêtir délimitant une zone critique (21), une anode (19), un bain électrolytique comprenant des particules insolubles, un support (12) sur lequel on monte ladite aube dans une position de travail par rapport à une paroi de référence (14), on place le support (12) dans ledit bain, et on réalise la co-déposition des particules et du métal de l'anode (19) afin de former le revêtement (20) sur la surface à revêtir. De façon caractéristique, ladite anode (19) est placée en regard de la zone critique (21) et ledit support (12) est équipé de moyens de contrôle des lignes de courant de façon à obtenir un revêtement (20) présentant une épaisseur prédéterminée et relativement constante pour la zone critique (21) et qui diminue progressivement jusqu'à une valeur sensiblement nulle le long des bords dudit revêtement (20).

ADJUSTABLE DEPLOYMENT DEVICE FOR A SEISMIC STATION ACTIVE FIXATION AND CONVEYED BY TUBING IN A WELL

SURGICAL INSTRUMENT WITH FIXING TELESCOPING

TOGETHER OF FIXING FOR TURBINE NOZZLE HAS GAS AND METHOD OF FIXING, OF DEMOUNTING AND INSTALLATION

Ensemble de fixation de distributeur de turbine, comportant une pièce extérieure (16) de turbine (une enveloppe ou une coque de turbine) pourvue d'une gorge périphérique (22) s'ouvrant dans une direction axiale orientée vers l'avant ; un segment (10) de distributeur comprenant une aube fixe (14) s'étendant entre des bandes intérieure et extérieure (12), la bande extérieure (12) étant pourvue d'un crochet annulaire dressé (20) muni d'un élément d'accrochage (23) s'étendant dans une direction axiale orientée vers l'arrière et reçu dans la gorge périphérique (22). Une rainure à orientation circonférentielle est formée dans le crochet annulaire dressé (20) et l'élément d'accrochage (23). Un bloc antirotation (32) est placé dans la rainure à orientation circonférentielle, et une plaque anti-basculement (36) ayant une largeur circonférentielle plus grande qu'une largeur circonférentielle correspondante de la rainure à orientation circonférentielle couvre sensiblement une face avant du bloc antirotation ...

PROCEEDED OF DEPOSIT BY ELECTROLYTIC WAY Of a COMPOSITE COATING HAS METAL MATRIX CONTAINING OF the PARTICLES, FOR the REPAIR Of a METAL PADDLE

CATALYST FOR NON-WOVEN MATERIALS CONTAINING GLASS FIBRES

PHARMACEUTICAL POSOLOGICAL FORMS OF BACLOFENE INTRATHECAL AND SYSTEM Of ADMINISTRATION ASSOCIATES

La présente invention concerne une configuration de dose et d'emballage qui comprend l'utilisation de seringues et de flacons pré-remplis à code couleur pour remplir et recharger des systèmes de perfusion de formes posologiques nouvelles et existantes de baclofène intrathécal.

SURGICAL INSTRUMENT WITH TELESCOPIC FIXING

PHARMACEUTICAL DOSAGE FORMS OF INTRATHECAL BACLOFEN AND DELIVERY SYSTEM THEREFOR

ANODE RAINUREE OF TANK Of ELECTROLYSIS

MODULATE MONOPIECE DRIVE

ADJUSTABLE DEVICE OF DEPLOYMENT FOR A SEISMIC STATION FIXEE IN AN ACTIVE WAY AND CONVOYEE BY CASING IN A WELL

Ce dispositif de couplage d'un mécanisme à capteur (200) à la surface d'un puits de forage (100) comprend un mandrin mis en place dans une colonne de tubage (105), un élément de support disposé sur le mandrin et ajustable axialement par rapport au mandrin, au moins un capteur (200) monté sur l'élément de support, le au moins un capteur étant raccordé à la surface du puits par une ligne formée d'un câble (135), et un dispositif de déploiement (300) disposé sur l'élément de support pour coupler le au moins un capteur à la surface du puits. Application notamment aux forages pétroliers.

ANODE RAINUREE OF TANK Of ELECTROLYSIS

L'invention a pour objet un bloc anodique (13, 13a-13e) en carbone pour anode précuite (4) pour utilisation dans une cellule d'électrolyse (1) de métal comportant une face supérieure (24), une face inférieure (23) destinée à être disposée en regard d'une face supérieure d'une cathode (9) et quatre faces latérales (21,22,34) et comprenant au moins une première rainure (31a-31e) débouchant sur au moins une des faces latérales, dans lequel la première rainure a une longueur maximale Lmax dans un plan parallèle à la face inférieure, et caractérisé en ce que la première rainure ne débouche pas sur lesdites faces inférieure ou supérieure, ou débouche sur lesdites faces inférieure ou supérieure sur une longueur Lo inférieure à la moitié de la longueur maximale Lmax.

PROCESS AND CONTROLLER Of an ENGINE STEP BY STEP ELECTRIC IN MODE ADEMI NOT

Procédé et appareil de commande (11) d'un moteur pas à pas électrique (1). Le moteur (1) est commandé par au moins un signal de commande (I1, I2) pour qu'au moins pendant l'application du signal de commande (I1, I2) au moteur pas à pas (1), on détecte un état de blocage du moteur pas à pas (22). Pour éviter des détections erronées, la détection de l'état de blocage (22) est seulement activée après que préalablement, pendant une durée prédéterminée on ait reconnu le fonctionnement en roue libre du moteur pas à pas (1).

THIENOPYRIMIDINE ALS KÜHLMITTEL

APPARATUS FOR CREATING OF ELECTRICAL CONNESTTION BETWEEN CONDUCTOR AND CONNECTING TERMINAL

Wager market creation and management

Methods and systems are provided herewith for creating and managing wagers on possible states within a live event, such as possible outcomes of subparts of a sporting event or other possible occurrences within the event. An initial state and multiple possible future states of a performance parameter of the event is determined based on state information of the event. A betting market may be created by determining probabilities and odds for the possible future states. The betting market is closed after bets are received and before an end of an initial state of the performance parameter. A payout may be made to a winner who selected the correct outcome of the performance parameter.

Integrated maintenance management system

A semi-automated maintenance management system instructs a technician to disassemble a component into parts, compare each part to a reference entry and identify any discrepancies between the part and the reference entry, repair or replace the component according to instructions automatically provided for the discrepancy when a known discrepancy is found, create a disposition when an unknown discrepancy is found, and reassemble the component.

SERPINC1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF

The invention relates to iRNA, e.g., double-stranded ribonucleic acid (dsRNA), compositions targeting the Serpinc1 gene, and methods of using such iRNA, e.g., dsRNA, compositions to inhibit expression of Serpinc1 and methods of treating subjects having a bleeding disorder, such as a hemophilia. 1. A double-stranded ribonucleic acid (dsRNA) for inhibiting expression of Serpinc1 , wherein said dsRNA comprises a sense strand and an antisense strand , wherein said sense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from the nucleotide sequence of SEQ ID NO:1 and said antisense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from the nucleotide sequence of SEQ ID NO:5.2. A double-stranded ribonucleic acid (dsRNA) for inhibiting expression of Serpinc1 , wherein said dsRNA comprises a sense strand and an antisense strand , the antisense strand comprising a region of complementarity which comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from any one of the antisense sequences listed in any one of Tables 3 , 4 , 8 , 11 , 12 , 14 , 15 , 20 , and 21.3. The dsRNA of claim 2 , wherein the sense and antisense strands comprise sequences selected from the group consisting of AD-50487.1 claim 2 , AD-50477.1 claim 2 , AD-50483.1 claim 2 , AD-50475.1 claim 2 , AD-50495.1 claim 2 , AD-50476.1 claim 2 , AD-50499.1 claim 2 , AD-50478.1 claim 2 , AD-50489.1 claim 2 , AD-50501.1 claim 2 , AD-50507.1 claim 2 , AD-50484.1 claim 2 , AD-50515.1 claim 2 , AD-50540.1 claim 2 , AD-50528.1 claim 2 , AD-50549.1 claim 2 , AD-50539.1 claim 2 , AD-50534.1 claim 2 , AD-50527.1 claim 2 , AD-50514.1 claim 2 , AD-50509.1 claim 2 , AD-50529.1 claim 2 , and AD-54944 and of any one of Tables 3 claim 2 , 4 claim 2 , 8 claim 2 , 11 claim 2 , 12 claim 2 , 14 claim 2 , 15 claim 2 , 20 claim 2 , and 21.4. The dsRNA of or claim 2 , wherein said dsRNA comprises at least one modified ...

Wave Powered Generator

The generator comprises: at least one energy capturing float () which is movable in response to wave motion; a reaction member () to be positioned below the energy capturing float; connecting lines () for connecting the at least one energy capturing float to the reaction member and defining a spacing (D) between the energy capturing float and the reaction member; energy convertors () for converting relative movement between the reaction member and at least one respective energy capturing float to useful energy. The generator includes depth setting means such as adjustable lines () connected to auxiliary floats () or adjustable mooring lines () securing the reaction member to the sea bed B for setting the depth (D) of the reaction member in the sea. 1. A generator for converting wave motion in a body of water to useful energy , the generator comprising:at least one energy capturing float which is movable in response to said wave motion;a reaction member to be positioned below the energy capturing float;a connector configured to connect said at least one energy capturing float to said reaction member and to define a distance between said energy capturing float and said reaction member;an energy convertor for converting relative movement between said reaction member and said at least one respective energy capturing float to the useful energy;wherein the generator includes a depth setting mechanism configured for setting the depth of the reaction member in the body of water.2. A generator according to claim 1 , in which the connector is of adjustable length for independently adjusting the distance between the energy capturing float and the reaction member claim 1 , independently of the depth setting mechanism.3. A generator according to claim 1 , in which the connector means comprises at least one flexible line claim 1 , the reaction member further having at least one drum around which the flexible line may be wound to achieve length adjustment of respective flexible ...

Stain removal through novel oxidizer and chelant combination

The present invention relates to a detergent composition comprising alkali metal carbonate, a chelant selected from the group consisting of MGDA, alkali metal tripolyphosphate, GLDA, and mixtures thereof, alkali metal percarbonate, and a peroxidation catalyst, wherein the molar ratio of chelant to alkali metal percarbonate is in the range of 1.8 to 3.4. The detergent composition is particularly suited for the removal of tea and coffee stains.

SERPINC1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF

The invention relates to iRNA, e.g., double-stranded ribonucleic acid (dsRNA), compositions targeting the Serpinc1 gene, and methods of using such iRNA, e.g., dsRNA, compositions to inhibit expression of Serpinc1 and methods of treating subjects having a bleeding disorder, such as a hemophilia. 1. A double-stranded ribonucleic acid (dsRNA) for inhibiting expression of Serpinc1 , wherein said dsRNA comprises a sense strand and an antisense strand , wherein said sense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from the nucleotide sequence of SEQ ID NO:1 and said antisense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from the nucleotide sequence of SEQ ID NO:5.2. A double-stranded ribonucleic acid (dsRNA) for inhibiting expression of Serpinc1 , wherein said dsRNA comprises a sense strand and an antisense strand , the antisense strand comprising a region of complementarity which comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from any one of the antisense sequences listed in any one of Tables 3 , 4 , 8 , 11 , 12 , 14 , 15 , 20 , and 21.3. The dsRNA of or , wherein said dsRNA comprises at least one modified nucleotide.4. The dsRNA of or , wherein the dsRNA comprises a sense strand consisting of a sense strand sequence selected from the sequence of any one of Tables 3 , 4 , 8 , 11 , 12 , 14 , 15 , 20 , and 21 , and an antisense strand consisting of an antisense sequence selected from the sequences of any one of Tables 3 , 4 , 8 , 11 , 12 , 14 , 15 , 20 , and 21.5. A cell containing the dsRNA of or .6. A vector encoding at least one strand of a dsRNA , wherein said dsRNA comprises a region of complementarity to at least a part of an mRNA encoding Serpinc1 , wherein said dsRNA is 30 base pairs or less in length , and wherein said dsRNA targets said mRNA for cleavage.7. A pharmaceutical composition for inhibiting expression of a Serpinc1 gene ...

Controlling display brightness when rendering composed scene-referred and output-referred content

Devices and methods for controlling display brightness may include receiving a brightness input for controlling a luminance level of at least one display in communication with the computer device. The devices and methods may include receiving high dynamic range (HDR) content and standard dynamic range (SDR) content for presentation on at least one display. The devices and methods may include generating adjusted SDR content by using the brightness input to modify luminance of the SDR content. The devices and methods may include blending the adjusted SDR content and the HDR content together to create a composed framebuffer content with the adjusted SDR content and the HDR content and transmitting the composed framebuffer content for presentation on at least one display.

COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF

The invention relates to iRNA, e.g., double-stranded ribonucleic acid (dsRNA), compositions targeting the complement component C5 gene, and methods of using such iRNA, e.g., dsRNA, compositions to inhibit expression of C5 and to treat subjects having a complement component C5-associated disease, e.g., paroxysmal nocturnal hemoglobinuria. 1. A double-stranded ribonucleic acid (dsRNA) agent for inhibiting expression of complement component C5 , wherein said dsRNA comprises a sense strand and an antisense strand forming a double stranded region , wherein said sense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from the nucleotide sequence of SEQ ID NO:1 and said antisense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from the nucleotide sequence of SEQ ID NO:5 , wherein substantially all of the nucleotides of the sense strand and substantially all of the nucleotides of the antisense strand are modified nucleotides.2. The dsRNA agent of claim 1 , wherein the antisense strand comprises a region of complementarity to an mRNA encoding complement component C5 claim 1 , wherein the region of complementarity comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from any one of the antisense nucleotide sequences listed in any one of Tables 3 claim 1 , 4 claim 1 , 5 claim 1 , 6 claim 1 , 18 claim 1 , 19 claim 1 , 20 claim 1 , 21 claim 1 , and 23.36.-. (canceled)7. The double stranded RNAi agent of claim 1 , wherein all of the nucleotides of said sense strand and all of the nucleotides of said antisense strand comprise a modification.8. The dsRNA agent of claim 1 , wherein at least one of said modified nucleotides is selected from the group consisting of a 3′-terminal deoxy-thymine (dT) nucleotide claim 1 , a 2′-O-methyl modified nucleotide claim 1 , a 2′-fluoro modified nucleotide claim 1 , a 2′-deoxy-modified nucleotide claim 1 , a locked nucleotide claim ...

ANGIOTENSINOGEN (AGT) iRNA COMPOSITIONS AND METHODS OF USE THEREOF

The present invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the angiotensinogen (AGT) gene, and methods of using such RNAi agents to inhibit expression of AGT and methods of treating subjects having an AGT-associated disorder, e.g., hypertension. 1. A double-stranded ribonucleic acid (RNAi) agent for inhibiting expression of angiotensinogen (AGT) in a cell , wherein said double-stranded RNAi agent comprises a sense strand and an antisense strand forming a double-stranded region , wherein said sense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from the nucleotide sequence of SEQ ID NO:1 , and said antisense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from the nucleotide sequence of SEQ ID NO:2 ,wherein substantially all of the nucleotides of said sense strand and substantially all of the nucleotides of said antisense strand are modified nucleotides, andwherein said sense strand is conjugated to a ligand attached at the 3′-terminus.2. The double-stranded ribonucleic acid RNAi agent of claim 1 ,wherein the sense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from nucleotides 2801-2101; 803-843; 834-859; 803-859; 803-875; 834-875; 847-875; 1247-1271; 1566-1624; 1570-1624; 1584-1624; 1584-1624; 1584-1621; 2035-2144; 2070-2144; 2070-2103; 2201-2223; 2227-2360; 2227-2304; 2290-2318; 2304-2350; 2304-2326; 2320-2342; 2333-2360; 2333-2358; 485-503; 517-535; 560-578; 635-653; 803-821; 814-832; 822-840; 825-843; 834-852; 837-855; 841-859; 855-873; 967-985; 1247-1265; 1248-1266; 1249-1267; 1251-1269; 1253-1271; 1566-1584; 1570-1588; 1572-1590; 1574-1592; 1584-1602; 1587-1605; 1591-1609; 1592-1610; 1595-1613; 1601-1619; 1602-1620; 1605-1623; 1729-1747; 1738-1756; 1739-1757; 1741-1769; 1767-1785; 1810-1828; 1827-1845; 1880-1989; 1892-1914; 1894-1914; 1894-2012; 2035-2053; 2046-2064; 2057-2075; 2070-2088; 2072- ...

Synergistic protein soil removal through novel chelator combination

The invention relates to a concentrated detergent composition comprising surfactant, alkali metal carbonate, methylglycinediacetic acid, glutamic acid N,N-diacetic acid, and alkali metal tripolyphosphate. The composition is particularly suited to remove protein soil in warewashing applications.

Silverwear Protective Supports

A protective support for an article of silverwear has a body with a lowermost interface to a tabletop and an uppermost region presenting a cradle opening vertically upward for restraining a silverwear utensil, the cradle having a bottom restraint supporting the silverwear utensil, and side restraints constraining the supported silverwear utensil from moving off the support on either side. 1. A protective support for an article of silverwear , comprising:a body having a lowermost interface to a tabletop and an uppermost region presenting a cradle opening vertically upward for restraining a silverwear utensil, the cradle having side restraints constraining the supported silverwear utensil from moving horizontally off the support on either side.2. The protective support of having a plurality of cradles implemented side to side for a plurality of silverwear utensils.3. The protective support of wherein the body is molded from a polymer material claim 2 , the cradles are v-shaped with a flat bottom and angled sidewalls providing a wider entrance than a width of the bottom of the cradle claim 2 , and wherein the lowermost interface to the tabletop is a flat claim 2 , planar surface.4. The protective support of wherein the body comprises a rearward portion with the cradles implemented therein claim 3 , and a forward portion comprising a forward support surface at a height less than a height of the flat bottom of the cradles.5. The protective support of comprising indicia on the forward support surface in front of each cradle claim 4 , the indicia indicating a specific silverwear utensil to be supported in the specific cradle associated with the indicia.6. The protective support of wherein the body is formed of a plurality of rectangular flat sheets joined along edges at angles such that lowermost joined edges provide the interface to the table top claim 1 , and uppermost joined edges provide v-shaped cradles opening upward for restraining silverwear utensils.7. The ...

Wagering on event outcomes during the event

Methods and systems are provided for managing a wagering system. In one exemplary embodiment, state information of a live event such as a sports game may be received in real time. During the event, a plurality of possible future states of the event and their associated probabilities (and odds) may be determined based on the state information, historical information, and current in-game information. A betting market is created for betting on the possible future states at determined odds. The betting market is closed, and winning and losing bets are resolved based on updated state information.

COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF

The invention relates to iRNA, e.g., double-stranded ribonucleic acid (dsRNA), compositions targeting the complement component C5 gene, and methods of using such iRNA, e.g., dsRNA, compositions to inhibit expression of C5 and to treat subjects having a complement component C5-associated disease, e.g., paroxysmal nocturnal hemoglobinuria. 1. A double-stranded ribonucleic acid (dsRNA) agent for inhibiting expression of complement component C5 , wherein said dsRNA comprises a sense strand and an antisense strand forming a double stranded region , wherein said sense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from the nucleotide sequence of SEQ ID NO:1 and said antisense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from the nucleotide sequence of SEQ ID NO:5 , wherein substantially all of the nucleotides of the sense strand and substantially all of the nucleotides of the antisense strand are modified nucleotides.2. The dsRNA agent of claim 1 , wherein the antisense strand comprises a region of complementarity to an mRNA encoding complement component C5 claim 1 , wherein the region of complementarity comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from any one of the antisense nucleotide sequences listed in any one of Tables 3 claim 1 , 4 claim 1 , 5 claim 1 , 6 claim 1 , 18 claim 1 , 19 claim 1 , 20 claim 1 , 21 claim 1 , and 23.36.-. (canceled)7. The double stranded RNAi agent of claim 1 , wherein all of the nucleotides of said sense strand and all of the nucleotides of said antisense strand comprise a modification.8. The dsRNA agent of claim 1 , wherein at least one of said modified nucleotides is selected from the group consisting of a 3′-terminal deoxy-thymine (dT) nucleotide claim 1 , a 2′-O-methyl modified nucleotide claim 1 , a 2′-fluoro modified nucleotide claim 1 , a 2′-deoxy-modified nucleotide claim 1 , a locked nucleotide claim ...

Power sources and transmission networks for auxiliary equipment onboard hydraulic fracturing units and associated methods

Embodiments of systems and methods disclosed provide a hydraulic fracturing unit that includes a reciprocating plunger pump configured to pump a fracturing fluid and a powertrain configured to power the reciprocating plunger pump. The powertrain includes a prime mover and a drivetrain, the prime mover including a gas turbine engine. The hydraulic fracturing unit also includes auxiliary equipment configured to support operation of the hydraulic fracturing unit including the reciprocating plunger pump and the powertrain. A power system is configured to power the auxiliary equipment. The power system includes a power source and a power network. The power source is configured to generate power for the auxiliary equipment. The power network is coupled to the power source and the auxiliary equipment, and configured to deliver the power generated by the power source to the auxiliary equipment. Associated systems including a plurality of hydraulic fracturing units are also provided.

NOVEL BIOMARKERS

The invention relates to biomarkers for predicting whether a patient infected with Hepatitis B virus (HBV) will respond to interferon (IFN) therapy. The invention also relates to methods and kits for predicting whether a patient will respond to IFN therapy using said biomarkers. 1. Use of CD220 as a biomarker to predict whether a patient infected with Hepatitis B virus (HBV) will respond to interferon (IFN) therapy.2. Use according to claim 1 , which comprises CD295 as a further biomarker.3. Use according to or claim 1 , which additionally comprises CD62L claim 1 , CD152 claim 1 , CDw329 and/or CD80 as further biomarkers.4. Use according to any one of to claim 1 , which additionally comprises CD66a and CD217b/r as further biomarkers.5. Use of CD220 and CD295 as a specific panel of biomarkers to predict whether a patient infected with Hepatitis B virus (HBV) will respond to interferon (IFN) therapy.6. Use according to any one of to claim 1 , wherein the biomarker is a soluble CD (sCD).7. Use according to any one of to claim 1 , wherein the interferon (IFN) therapy is alpha interferon therapy.8. Use according to claim 7 , wherein the alpha interferon therapy comprises the use of interferon alpha-2a.9. Use according to claim 7 , wherein the alpha interferon therapy comprises the use of interferon alpha-2b.10. Use according to any one of to claim 7 , wherein the alpha interferon therapy comprises the use of pegylated alpha interferon.11. Use according to any one of to claim 7 , wherein the alpha interferon therapy comprises the use of non-pegylated alpha interferon.12. Use according to any one of to claim 7 , wherein the patient infected with Hepatitis B virus (HBV) is chronically infected.13. Use according to any one of to claim 7 , wherein the patient infected with Hepatitis B virus (HBV) is HBV e antigen (HBeAg) positive (e+).14. A method of predicting whether a patient infected with Hepatitis B virus (HBV) will respond to interferon therapy claim 7 , comprising:(a) ...

Method of controlling the operation of a range extended plug-in hybrid electric vehicle

A method for operating a hybrid electric vehicle including determining a period of time and a speed of crankshaft rotation inducing lubricant delivery to a lubricated component in an internal combustion engine of a vehicle based on an ambient temperature and when a period of combustion inactivity exceeds a threshold and a state of charge of an electrical storage device is above a limit and attached to an external power source, rotating the crankshaft for the duration and speed using an electric machine.

ANGIOTENSINOGEN (AGT) iRNA COMPOSITIONS AND METHODS OF USE THEREOF

The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the AGT gene. The invention also relates to methods of using such RNAi agents to inhibit expression of an AGT gene and to methods of preventing and treating an AGT-associated disorder, e.g., high blood pressure. 1. A double stranded ribonucleic acid (dsRNA) agent , or a salt thereof , for inhibiting expression of angiotensinogen (AGT) in a cell ,wherein the dsRNA agent, or salt thereof, comprises a sense strand and an antisense strand forming a double stranded region,wherein the antisense strand comprises at least 19 contiguous nucleotides of the nucleotide sequence of 5′-UGUACUCUCAUUGUGGAUGACGA-3′ (SEQ ID NO:298), wherein substantially all of the nucleotides of the sense strand and substantially all of the nucleotides of the antisense strand comprise a modification, and wherein at least one of the modifications is a thermally destabilizing nucleotide modification.2. The dsRNA agent claim 1 , or salt thereof claim 1 , of claim 1 , wherein the antisense strand comprises at least 21 contiguous nucleotides of the nucleotide sequence of 5′-UGUACUCUCAUUGUGGAUGACGA-3′ (SEQ ID NO:298).3. The dsRNA agent claim 1 , or salt thereof claim 1 , of claim 1 , wherein all of the nucleotides of the sense strand and all of the nucleotides of the antisense strand comprise a modification.4. The dsRNA agent claim 1 , or salt thereof claim 1 , of claim 1 , wherein the thermally destabilizing nucleotide modification is selected from the group consisting of an abasic modification; a mismatch with the opposing nucleotide in the duplex; and destabilizing sugar modification claim 1 , a 2′-deoxy modification claim 1 , an acyclic nucleotide claim 1 , an unlocked nucleic acids (UNA) claim 1 , and a glycerol nucleic acid (GNA).5. The dsRNA agent claim 1 , or salt thereof claim 1 , of claim 1 , wherein at least one of the modified nucleotides is selected from the group consisting of a deoxy-nucleotide ...

COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF

The invention relates to iRNA, e.g., double-stranded ribonucleic acid (dsRNA), compositions targeting the complement component C5 gene, and methods of using such iRNA, e.g., dsRNA, compositions to inhibit expression of C5 and to treat subjects having a complement component C5-associated disease, e.g., paroxysmal nocturnal hemoglobinuria. 1. A double stranded ribonucleic acid (dsRNA) agent for inhibiting expression of complement component C5 , wherein said dsRNA comprises a sense strand and an antisense strand , wherein said sense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from the nucleotide sequence of SEQ ID NO:1 and said antisense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from the nucleotide sequence of SEQ ID NO:5.2. A double stranded ribonucleic acid (dsRNA) agent for inhibiting expression of complement component C5 , wherein said dsRNA comprises a sense strand and an antisense strand , the antisense strand comprising a region of complementarity which comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from any one of the antisense sequences listed in any one of Tables 3 , 4 , 5 , 6 , 18 , 19 , 20 , 21 , and 23.3. The dsRNA agent of claim 1 , wherein said dsRNA agent comprises at least one modified nucleotide.4. A double stranded ribonucleic acid (dsRNA) agent for inhibiting expression of complement component C5 claim 1 , wherein said dsRNA agent comprises a sense strand and an antisense strand forming a double-stranded region claim 1 ,wherein said sense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from the nucleotide sequence of SEQ ID NO:1 and said antisense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from the nucleotide sequence of SEQ ID NO:5,wherein substantially all of the nucleotides of said sense strand and substantially all of ...

BEARING FOR A CARDIAC PUMP

A plain bearing assembly for a cardiac pump, the plain bearing assembly comprising; a rotational portion which, in use, rotates with a cardiac pump rotor, the rotational portion configured to engage a stationary portion of a cardiac pump housing, the stationary portion comprising one or more first bearing surfaces and the rotational portion comprising one or more second bearing surfaces, the one or more second bearing surfaces configured so as to be in contact with the one or more first bearing surfaces, therein defining a bearing interface between the one or more first bearing surfaces and the one or more second bearing surfaces during rotation of the rotational portion, wherein the rotational portion comprises one or more first flow channels configured to interrupt the bearing interface and permit blood to flow between an outside of the plain bearing assembly and a center of the plain bearing assembly. 1. A plain bearing assembly for a cardiac pump , the plain bearing assembly comprising:a first bearing portion, the first bearing portion being configured to engage a second bearing portion, one of the first bearing portion and the second bearing portion being configured to rotate with a cardiac pump rotor, the first bearing portion comprising one or more first bearing surfaces and the second bearing portion comprising one or more second bearing surfaces, the one or more first bearing surfaces being configured so as to be in contact with the one or more second bearing surfaces so as to define a bearing interface between the one or more first bearing surfaces and the one or more second bearing surfaces during rotation of the cardiac pump rotor,wherein the first bearing portion comprises one or more first flow channels configured to interrupt the bearing interface and permit blood to flow between an outside of the plain bearing assembly and a centre of the plain bearing assembly.2. The plain bearing assembly according to claim 1 , wherein the first bearing portion ...

Cardiac Pump

A cardiac pump includes a plain bearing assembly having a first plain bearing portion that is coupled to a cardiac pump rotor and a second plain bearing portion that is coupled to a cardiac pump housing. The plain bearing assembly is configured to rotatably support the cardiac pump rotor within the cardiac pump housing in at least an axial direction of the cardiac pump rotor. A magnetic bearing assembly includes a first magnetic bearing portion that is coupled to the cardiac pump rotor and a second magnetic bearing portion that is coupled to the cardiac pump housing. The magnetic bearing assembly is configured to rotatably support the cardiac pump rotor within the cardiac pump housing in a radial direction of the cardiac pump rotor and bias the cardiac pump rotor in the axial direction such that the magnetic bearing assembly provides a preload force to preload the plain bearing assembly. 1. A cardiac pump comprising:a plain bearing assembly comprising a first plain bearing portion and a second plain bearing portion, the first plain bearing portion being coupled to a cardiac pump rotor and the second plain bearing portion being coupled to a cardiac pump housing, the plain bearing assembly being configured to rotatably support the cardiac pump rotor within the cardiac pump housing in at least an axial direction of the cardiac pump rotor; anda magnetic bearing assembly comprising a first magnetic bearing portion and a second magnetic bearing portion, the first magnetic bearing portion being coupled to the cardiac pump rotor and the second magnetic bearing portion being coupled to the cardiac pump housing, the magnetic bearing assembly being configured to rotatably support the cardiac pump rotor within the cardiac pump housing in a radial direction of the cardiac pump rotor and bias the cardiac pump rotor in the axial direction such that the magnetic bearing assembly provides a preload force to preload the plain bearing assembly.2. A cardiac pump according to claim 1 , ...

TMPRSS6 iRNA COMPOSITIONS AND METHODS OF USE THEREOF

The invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the TMPRSS6 gene, and methods of using such RNAi agents to inhibit expression of TMPRSS6 and methods of treating subjects having a TMPRSS6 associated disorder, e.g., an iron overload associated disorder, such as β-thalassemia or hemochromatosis. 1. A double stranded RNAi agent for inhibiting expression of TMPRSS6 in a cell , wherein said double stranded RNAi agent comprises a sense strand and an antisense strand forming a duplex , wherein the sense strand and the antisense strand comprise the sense and antisense strand nucleotide sequences of any one of the duplexes provided in any one of Tables 6 , 7 , and 8.2. The double stranded RNAi agent of claim 1 , wherein the sense strand and the antisense strand comprise the sense and antisense strand nucleotide sequences of a duplex selected from the group consisting of AD-63202 claim 1 , AD-64372 claim 1 , AD-64373 claim 1 , AD-64374 claim 1 , AD-64375 claim 1 , AD-64376 claim 1 , AD-64377 claim 1 , AD-64378 claim 1 , AD-64380 claim 1 , AD-64381 claim 1 , AD-64382 claim 1 , AD-64384 claim 1 , AD-64385 claim 1 , AD-64386 claim 1 , AD-64387 claim 1 , AD-64389 claim 1 , AD-64601 claim 1 , AD-64569 claim 1 , AD-64604 claim 1 , AD-64567 claim 1 , AD-60940 claim 1 , AD-64601 claim 1 , AD-65105 claim 1 , AD-65106 claim 1 , AD-65107 claim 1 , AD-65108 claim 1 , AD-65109 claim 1 , AD-65110 claim 1 , AD-65111 claim 1 , AD-65112 claim 1 , AD-61002 claim 1 , AD-66014 claim 1 , AD-66015 claim 1 , and AD-65189.35.-. (canceled)6. The double stranded RNAi agent of claim 1 , further comprising a ligand.7. The double stranded RNAi agent of claim 6 , wherein the ligand is one or more GalNAc derivatives attached through a bivalent or trivalent branched linker.9. The double stranded RNAi agent of claim 6 , wherein the ligand is attached to the 3′ end of the sense strand.1112-. (canceled)13. A pharmaceutical composition comprising the double stranded RNAi agent ...

Care event detection and alerts

An occurrence of one or more “care events” is detected by an electronic device monitoring environmental data and/or user data from one or more sensors. The electronic device transmits one or more alerts regarding the detected occurrence to at least one other electronic device. In some cases, the electronic device may cooperate with at least one other electronic device in monitoring, detecting, and/or transmitting. For example, the electronic device may detect the occurrence based on sensor data received from a cooperative electronic device or such data in combination with the electronic device's sensor data. By way of another example, the electronic device may detect the occurrence and signal a cooperative electronic device to transmit one or more alerts.

Drive Assembly

A drive assembly is provided suitable for aiding in the conversion of wave energy to useful energy. The drive assembly of the present invention is arranged to transfer wave energy to an energy converter, the drive assembly comprising a wave energy capturing member; and a lever arm coupled to the wave energy capturing member, the lever arm being movable between a first stroke position and a second stroke position to define a working stroke; wherein the lever arm is arranged to be coupled to an energy converter and is further arranged to transfer energy from the wave energy capturing member to said energy converter; further wherein the wave energy capturing member is arranged to move the lever arm between the first stroke position and the second stroke position; and wherein the first stroke position and the second stroke position define distal end points of the working stroke; the working stroke arranged so as to drive said energy converter. 1. A drive assembly arranged to transfer wave energy to an energy converter , the drive assembly comprising ,a wave energy capturing member;an actuating member in communication with the wave energy capturing member, and arranged to transfer energy from the wave energy capturing member; and wherein the lever arm is arranged to be coupled to an energy converter and is further arranged to transfer energy from the wave energy capturing member to said energy converter;', 'further wherein the wave energy capturing member is arranged to move the lever arm between the first stroke position and the second stroke position; and', 'wherein the first stroke position and the second stroke position define distal end points of the working stroke; the working stroke arranged so as to drive said energy converter., 'a lever arm coupled to the wave energy capturing member, the lever arm being movable between a first stroke position and a second stroke position to define a working stroke;'}2. A drive assembly as claimed in claim 1 , wherein the ...

FLUID PUMP

A fluid pump for conveying a fluid is provided comprising: a housing with a fluid inlet and a fluid outlet, a rotor which is disposed rotatably about an axis of rotation in the housing, and a rotor body and at least one conveying element connected rigidly to the rotor body in order to convey the fluid from the fluid inlet to the fluid outlet, the rotor being mounted in the housing radially to the axis of rotation by means of a passive magnetic bearing and also axially and radially by means of a mechanical and/or hydrodynamic bearing disposed on the inlet side or outlet side. A safety bearing is disposed on one side of the rotor situated opposite the mechanical and/or hydrodynamic bearing, wherein the safety bearing has a first safety bearing component connected rigidly to the rotor and a second safety bearing component connected rigidly to the housing. 1. A fluid pump for conveying a fluid comprising:a housing with a fluid inlet and a fluid outlet,a rotor which is disposed rotatably about an axis of rotation in the housing, anda rotor body and at least one conveying element connected rigidly to the rotor body in order to convey the fluid from the fluid inlet to the fluid outlet,the rotor being mounted in the housing radially to the axis of rotation by means of a passive magnetic bearing and also axially and radially by means of a mechanical and/or hydrodynamic bearing disposed on the inlet side or outlet side,whereina safety bearing being disposed on one side of the rotor situated opposite the mechanical and/or hydrodynamic bearing, wherein the safety bearing has a first safety bearing component connected rigidly to the rotor and a second safety bearing component connected rigidly to the housing, during operation of the fluid pump, an axial and radial spacing between the first and the second safety bearing component being greater than a radial minimal spacing between the rotor and the housing, and the safety bearing being equipped to restrict deflection of the rotor ...

ANGIOTENSINOGEN (AGT) iRNA COMPOSITIONS AND METHODS OF USE THEREOF

The present invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the angiotensinogen (AGT) gene, and methods of using such RNAi agents to inhibit expression of AGT and methods of treating subjects having an AGT-associated disorder, e.g., hypertension. 1. A double-stranded ribonucleic acid (RNAi) agent for inhibiting expression of angiotensinogen (AGT) in a cell , wherein said double-stranded RNAi agent comprises a sense strand and an antisense strand forming a double-stranded region , wherein said sense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from the nucleotide sequence of SEQ ID NO: 1 , and said antisense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from the nucleotide sequence of SEQ ID NO:2 ,wherein substantially all of the nucleotides of said sense strand and substantially all of the nucleotides of said antisense strand are modified nucleotides, andwherein said sense strand is conjugated to a ligand attached at the 3′-terminus.2. A double-stranded ribonucleic acid (RNAi) agent for inhibiting expression of angiotensinogen (AGT) in a cell , wherein said double-stranded RNAi agent comprises a sense strand and an antisense strand forming a double-stranded region ,wherein the sense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from nucleotides 2801-2101; 803-843; 834-859; 803-859; 803-875; 834-875; 847-875; 1247-1271; 1566-1624; 1570-1624; 1584-1624; 1584-1624; 1584-1621; 2035-2144; 2070-2144; 2070-2103; 2201-2223; 2227-2360; 2227-2304; 2290-2318; 2304-2350; 2304-2326; 2320-2342; 2333-2360; 2333-2358; 485-503; 517-535; 560-578; 635-653; 803-821; 814-832; 822-840; 825-843; 834-852; 837-855; 841-859; 855-873; 967-985; 1247-1265; 1248-1266; 1249-1267; 1251-1269; 1253-1271; 1566-1584; 1570-1588; 1572-1590; 1574-1592; 1584-1602; 1587-1605; 1591-1609; 1592-1610; 1595-1613; 1601-1619; 1602-1620; 1605-1623 ...

METHOD FOR REPLICATING HCV IN VITRO

There is provided a method for replicating HCV virus in vitro which comprises the following steps: (i) fusing an HCV-infected white blood cell with a hepatocyte cell to produce a fused cell; and (ii) culturing the fused cell so that HCV replication may occur. There is also provided a fused cell capable of replicating HCV virus in vitro which is made by fusing an HCV-infected white blood cell with a hepatocyte cell, and uses of such a fused cell to screen for anti-HCV drugs and assessing patient responsiveness to therapy before treatment. 1. A method for replicating HCV virus in vitro which comprises the following steps:(i) fusing an HCV-infected white blood cell with a hepatocyte cell to produce a fused cell; and(ii) culturing the fused cell so that HCV replication may occur.2. A method according to claim 1 , wherein the HCV-infected white blood cell is isolated from an HCV patient.3. A method according to claim 2 , wherein the HCV-infected white blood cell is made by infecting a white blood cell with HCV virus in vitro.4. A method according to claim 3 , wherein the white blood cell is derivable from a white blood cell line.5. A method according to or claim 3 , wherein the white blood cell has been pre-treated with at least one pro-inflammatory reagent.6. A method according to any preceding claim claim 3 , wherein the white blood cell is a monocyte.7. A method according to any preceding claim claim 3 , in which white blood cell is infected with HCV virus having HCV genotype 2 claim 3 , 3 claim 3 , 4 claim 3 , 5 claim 3 , or 6.8. A fused cell capable of replicating HCV virus in vitro which is made by fusing an HCV-infected white blood cell with a hepatocyte cell.9. A method for making a fused cell according to claim 8 , which comprises the step of fusing an HCV-infected white blood cell with a hepatocyte cell in vitro.10. A method according to claim 9 , wherein the HCV-infected white blood cell is derived from a HCV patient.11. A method according to claim 9 , wherein ...

Surgical tool systems and methods

Embodiments of the present disclosure provide a surgical robot system may include an end-effector element configured for controlled movement and positioning and tracking of surgical instruments and objects relative to an image of a patient's anatomical structure. In some embodiments the end-effector may be tracked by surgical robot system and displayed to a user. In some embodiments the end-effector element may be configured to restrict the movement of an instrument assembly in a guide tube. In some embodiments, the end-effector may contain structures to allow for magnetic coupling to a robot arm and/or wireless powering of the end-effector element. In some embodiments, tracking of a target anatomical structure and objects, both in a navigation space and an image space, may be provided by a dynamic reference base located at a position away from the target anatomical structure.

SERPINC1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF

The invention relates to iRNA, e.g., double-stranded ribonucleic acid (dsRNA), compositions targeting the Serpinc1 gene, and methods of using such iRNA, e.g., dsRNA, compositions to inhibit expression of Serpinc1 and methods of treating subjects having a bleeding disorder, such as a hemophilia. 1. A double-stranded ribonucleic acid (dsRNA) for inhibiting expression of Serpinc1 , wherein said dsRNA comprises a sense strand and an antisense strand , wherein said sense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from the nucleotide sequence of SEQ ID NO:1 and said antisense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from the nucleotide sequence of SEQ ID NO:5.2. A double-stranded ribonucleic acid (dsRNA) for inhibiting expression of Serpinc1 , wherein said dsRNA comprises a sense strand and an antisense strand , the antisense strand comprising a region of complementarity which comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from any one of the antisense sequences listed in any one of Tables 3 , 4 , 8 , 11 , 12 , 14 , 15 , 20 , and 21.3. The dsRNA of claim 1 , wherein said dsRNA comprises at least one modified nucleotide.4. The dsRNA of claim 1 , wherein the dsRNA comprises a sense strand consisting of a sense strand sequence selected from the sequence of any one of Tables 3 claim 1 , 4 claim 1 , 8 claim 1 , 11 claim 1 , 12 claim 1 , 14 claim 1 , 15 claim 1 , 20 claim 1 , and 21 claim 1 , and an antisense strand consisting of an antisense sequence selected from the sequences of any one of Tables 3 claim 1 , 4 claim 1 , 8 claim 1 , 11 claim 1 , 12 claim 1 , 14 claim 1 , 15 claim 1 , 20 claim 1 , and 21.5. A cell containing the dsRNA of .6. A vector encoding at least one strand of a dsRNA claim 1 , wherein said dsRNA comprises a region of complementarity to at least a part of an mRNA encoding Serpinc1 claim 1 , wherein said dsRNA is 30 base ...

SERPINC1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF

The invention relates to iRNA, e.g., double-stranded ribonucleic acid (dsRNA), compositions targeting the Serpinc1 gene, and methods of using such iRNA, e.g., dsRNA, compositions to inhibit expression of Serpinc1 and methods of treating subjects having a bleeding disorder, such as a hemophilia. 1. A double-stranded ribonucleic acid (dsRNA) for inhibiting expression of Serpinc1 , wherein said dsRNA comprises a sense strand and an antisense strand , wherein said sense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from the nucleotide sequence of SEQ ID NO: 1 and said antisense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from the nucleotide sequence of SEQ ID NO:5.2. A double-stranded ribonucleic acid (dsRNA) for inhibiting expression of Serpinc1 , wherein said dsRNA comprises a sense strand and an antisense strand , the antisense strand comprising a region of complementarity which comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from anyone of the antisense sequences listed in any one of Tables 3 , 4 ,8 , 11 , 12 , 14 , 15 , 20 , and 21.3. The dsRNA of claim 1 , wherein said dsRNA comprises at least one modified nucleotide.4. The dsRNA of claim 1 , wherein the dsRNA comprises a sense strand consisting of a sense strand sequence selected from the sequence of anyone of Tables 3 claim 1 , 4 claim 1 , 8 claim 1 , 11 claim 1 , 12 claim 1 , 14 claim 1 , 15 claim 1 , 20 claim 1 , and 21 claim 1 , and an antisense strand consisting of an antisense sequence selected from the sequences of anyone of Tables 3 claim 1 , 4 claim 1 , 8 claim 1 , 11 claim 1 , 12 claim 1 , 14 claim 1 , 15 claim 1 , 20 claim 1 , and 21.5. A cell containing the dsRNA of .6. A vector encoding at least one strand of a dsRNA claim 1 , wherein said dsRNA comprises a region of complementarity to at least a part of an mRNA encoding Serpinc1 claim 1 , wherein said dsRNA is 30 base ...

COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF

The invention relates to iRNA, e.g., double-stranded ribonucleic acid (dsRNA), compositions targeting the complement component C5 gene, and methods of using such iRNA, e.g., dsRNA, compositions to inhibit expression of C5 and to treat subjects having a complement component C5-associated disease, e.g., paroxysmal nocturnal hemoglobinuria. 1. A double-stranded ribonucleic acid (dsRNA) agent for inhibiting expression of complement component C5 , wherein said dsRNA agent comprises a sense strand and an antisense strand , the antisense strand comprising a region of complementarity which comprises at least 17 contiguous nucleotides differing by no more than 3 nucleotides from the nucleotide sequence of 5′-UAUUAUAAAAAUAUCUUGCUUUU-3′ (SEQ ID NO:113) , and wherein said dsRNA agent comprises at least one modified nucleotide.2. A double-stranded ribonucleic acid (dsRNA) agent for inhibiting expression of complement component C5 , wherein said dsRNA agent comprises a sense strand and an antisense strand , the antisense strand comprising a region of complementarity which comprises at least 17 contiguous nucleotides differing by no more than 3 nucleotides from the nucleotide sequence of 5′-UAUUAUAAAAAUAUCUUGCUUUU-3′ (SEQ ID NO:113).wherein substantially all of the nucleotides of said sense strand and substantially all of the nucleotides of said antisense strand are modified nucleotides, andwherein said sense strand is conjugated to a ligand attached at the 3′-terminus.3. The dsRNA agent of claim 2 , wherein all of the nucleotides of said sense strand and all of the nucleotides of said antisense strand are modified nucleotides.4. The dsRNA agent of claim 2 , wherein the modified nucleotide is selected from the group consisting of a 3′-terminal deoxy-thymine (dT) nucleotide claim 2 , a 2′-O-methyl modified nucleotide claim 2 , a 2′-fluoro modified nucleotide claim 2 , a 2′-deoxy-modified nucleotide claim 2 , a locked nucleotide claim 2 , an abasic nucleotide claim 2 , a 2′-amino- ...

Wave Powered Generator

A generator for capturing and converting wave energy into a more useful form is provided. The generator comprises: at least one energy capturing float () which is movable in response to wave motion; a reaction member () to be positioned below the energy capturing float; connecting lines () for connecting the at least one energy capturing float to the reaction member and defining a spacing (D) between the energy capturing float and the reaction member; energy convertors () for converting relative movement between the reaction member and at least one respective energy capturing float to useful energy. The generator includes depth setting means such as adjustable mooring lines () securing the reaction member to the sea bed SB for setting the depth (D) of the reaction member in the sea. Both the float and the reaction member possess a positive buoyancy, allowing suitable tension to be applied to the mooring lines. The improved tension brought about by the net positive buoyancy has the surprising effect of improved stability in energetic sea conditions. 1. A generator for converting wave motion in a body of water to useful energy , the generator comprising: at least one energy capturing float which is movable in response to said wave motion; a reaction member to be positioned below the energy capturing float; connection means for connecting said at least one energy capturing float to said reaction member; energy conversion means for converting relative movement between said reaction member and said at least one respective energy capturing float to the useful energy; wherein the generator includes adaptable depth setting means for setting , over a predetermined range , the depth of the reaction member in the body of water and the height of the reaction member from a bed of the body of water , characterised in that both the float and the reaction member have a positive buoyancy.2. A generator as claimed in claim 1 , wherein the connecting means defines a distance between ...

SERPINC1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF

The invention relates to iRNA, e.g., double-stranded ribonucleic acid (dsRNA), compositions targeting the Serpinc1 gene, and methods of using such iRNA, e.g., dsRNA, compositions to inhibit expression of Serpinc1 and methods of treating subjects having a bleeding disorder, such as a hemophilia. 1. A method of treating a subject having a hemophilia , comprising administering to the subject a therapeutically effective amount of a double stranded ribonucleic acid (dsRNAi) agent ,wherein the dsRNAi agent comprises a sense strand and an antisense strand,wherein said sense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from the nucleotide sequence of SEQ ID NO:1 and said antisense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from the nucleotide sequence of SEQ ID NO:5, thereby treating the subject having a hemophilia.2. A method of treating a subject having a hemophilia , comprising administering to the subject a therapeutically effective amount of a double stranded ribonucleic acid (dsRNAi) agent ,wherein the dsRNAi agent comprises a sense strand and an antisense strand, wherein the antisense strand comprises a region of complementarity which comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from the nucleotide sequence of SEQ ID NO:5, thereby treating the subject having a hemophilia.3. A method of preventing at least one symptom in a subject having a hemophilia , comprising administering to the subject a therapeutically effective amount of a double stranded ribonucleic acid (dsRNAi) agent ,wherein the dsRNAi agent comprises a sense strand and an antisense strand,wherein said sense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from the nucleotide sequence of SEQ ID NO:1 and said antisense strand comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from the nucleotide ...

ANGIOTENSINOGEN (AGT) iRNA COMPOSITIONS AND METHODS OF USE THEREOF

The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the AGT gene. The invention also relates to methods of using such RNAi agents to inhibit expression of an AGT gene and to methods of preventing and treating an AGT-associated disorder, e.g., high blood pressure. 130.-. (canceled)31. A double stranded ribonucleic acid (dsRNA) agent , or a salt thereof , for inhibiting expression of angiotensinogen (AGT) , wherein the dsRNA agent comprises a sense strand and an antisense strand forming a double stranded region , wherein the sense strand comprises at least 19 contiguous nucleotides from any one of the nucleotide sequence of nucleotides 635-658 , 636-658 , 642-667 , 642-664 , 645-667 , 1248-1273 , 1248-1272 , 1248-1270 , 1250-1272 , 1251-1273 , 1580-1602 , 1584-1606 , 1587-1609 , 1601-1623 , 1881-1903 , 2074-2097 , 2074-2096 , 2075-2097 , 2080-2102 , 2272-2294 , 2276-2298 , 2281-2304 , 2281-2303 , or 2282-2304 of SEQ ID NO:1 , and the antisense strand comprises at least 19 contiguous nucleotides from the nucleotide sequence of SEQ ID NO:2.32. The dsRNA agent claim 31 , or salt thereof claim 31 , of claim 31 , wherein substantially all of the nucleotides of the sense strand and substantially all of the nucleotides of the antisense strand are modified nucleotides.33. The dsRNA agent claim 32 , or salt thereof claim 32 , of claim 32 , wherein at least one of the modified nucleotides is selected from the group consisting of a deoxy-nucleotide claim 32 , a 3′-terminal deoxy-thymine (dT) nucleotide claim 32 , a 2′-O-methyl modified nucleotide claim 32 , a 2′-fluoro modified nucleotide claim 32 , a 2′-deoxy-modified nucleotide claim 32 , a locked nucleotide claim 32 , an unlocked nucleotide claim 32 , a conformationally restricted nucleotide claim 32 , a constrained ethyl nucleotide claim 32 , an abasic nucleotide claim 32 , a 2′-amino-modified nucleotide claim 32 , a 2′-O-allyl-modified nucleotide claim 32 , 2′-C-alkyl-modified ...

COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF

The invention relates to iRNA, e.g., double-stranded ribonucleic acid (dsRNA), compositions targeting the complement component C5 gene, and methods of using such iRNA, e.g., dsRNA, compositions to inhibit expression of C5 and to treat subjects having a complement component C5-associated disease, e.g., paroxysmal nocturnal hemoglobinuria.

Cardiac Pump

A cardiac pump () includes a cardiac pump housing () having a blood inlet () that is offset from the longitudinal axis of the cardiac pump housing (). 118-. (canceled)19. A cardiac pump comprising a cardiac pump housing having a blood inlet that is offset from a longitudinal axis of the cardiac pump housing , the blood inlet being configured to flow blood radially across a contact bearing interface of a plain bearing assembly of the cardiac pump.20. A cardiac pump according to claim 19 , the cardiac pump housing is configured to extend at least partially through a wall of a heart.21. A cardiac pump according to claim 19 , wherein the blood inlet is positioned within the heart when the cardiac pump is implanted at least partially in the heart.22. A cardiac pump according to claim 19 , wherein the blood inlet comprises one or more openings having a center of area that is offset from the longitudinal axis of the cardiac pump housing.231. A cardiac pump according to claim 19 , wherein the blood inlet has a rotational symmetry of order about the longitudinal axis of the cardiac pump housing.24. A cardiac pump according to claim 19 , wherein the blood inlet is non-axisymmetric.25. A cardiac pump according to claim 19 , the cardiac pump comprising at least one bearing assembly configured to rotatably support a cardiac pump rotor within the cardiac pump housing claim 19 , wherein the blood inlet is configured to divert radially the flow of blood across the at least one bearing assembly.26. A cardiac pump according to claim 25 , wherein the at least one bearing assembly comprises a contact bearing having a first contact bearing portion configured to engage a second contact bearing portion thereby defining a contact bearing interface claim 25 , the blood inlet being configured to divert radially the flow of blood across the contact bearing interface of the at least one bearing assembly.27. A cardiac pump according to claim 26 , wherein the cardiac pump housing defines a blood ...

Centrifugal Pump

The pump, which is for implantation into a human heart, has a flow path through a housing (), a rotatable pump member () within the housing for causing fluid to flow along the flow path, the pump member being rotatably coupled to the housing about an upstream bearing () and a downstream bearing (). The downstream bearing comprises a bearing member () on the pump member and a complementary bearing formation () on the housing, The pump has a mechanical adjuster () for fine adjustment of the position of the bearing formation () along an axis (A) of the pump member; the mecahnical adjuster being preferably one or more screws () for adjustable movement of a boss () along the axis (A), the adjustable movement being permitted by flexure of a plate member () integral with the boss. 114-. (canceled)15. A centrifugal pump comprising:a) a housing comprising a fluid inlet, a fluid outlet, a flow path which extends between the fluid inlet and the fluid outlet, and a plate member forming part of the housing;b) a rotatable pump member including an impeller configured to rotate about an axis of the pump member, the impeller being within the housing and configured to cause fluid to flow along said flow path from said fluid inlet to said fluid outlet;c) an upstream bearing for coupling the pump member to the housing;d) a downstream bearing comprising a bearing member on the pump member and a bearing formation on the housing, said bearing formation being complementary to said bearing member; ande) a mechanical adjuster for fine adjustment of the position of said bearing formation along the axis of the pump member, said mechanical adjuster being configured to flex the plate member and move the bearing member along the axis of the pump member.16. A pump according to claim 15 , wherein the bearing formation is provided in a boss integral with the plate member.17. A pump according to claim 16 , wherein the boss has an outer circumferential surface and the bearing member has an inner ...

Social media rule engine

A computer implemented method includes receiving instructions from a user for identifying data on one or more social networks, wherein the instructions received from the user comprise one or more conditions and one or more actions, identifying, on the one or more social networks, data that is associated with one or more social entities, determining one or more characteristics of the identified data, determining, based on the one or more characteristics of the identified data, that the identified data meets one or more conditions for identifying data specified in the instructions received from the user, in response to determining that the identified data meets one or more conditions specified in the instructions received from the user, performing one or more actions specified in the instructions received from the user.

TMPRSS6 iRNA COMPOSITIONS AND METHODS OF USE THEREOF

The invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the TMPRSS6 gene, and methods of using such RNAi agents to inhibit expression of TMPRSS6 and methods of treating subjects having a TMPRSS6 associated disorder, e.g., an iron overload associated disorder, such as β-thalassemia or hemochromatosis. 1. A double stranded RNAi agent for inhibiting expression of TMPRSS6 in a cell , wherein said double stranded RNAi agent comprises a sense strand and an antisense strand forming a duplex , wherein the sense strand and the antisense strand comprise the sense and antisense strand nucleotide sequences of any one of the duplexes provided in any one of Tables 6 , 7 , and 8.2. The double stranded RNAi agent of claim 1 , wherein the sense strand and the antisense strand comprise the sense and antisense strand nucleotide sequences of a duplex selected from the group consisting of AD-63202 claim 1 , AD-64372 claim 1 , AD-64373 claim 1 , AD-64374 claim 1 , AD-64375 claim 1 , AD-64376 claim 1 , AD-64377 claim 1 , AD-64378 claim 1 , AD-64380 claim 1 , AD-64381 claim 1 , AD-64382 claim 1 , AD-64384 claim 1 , AD-64385 claim 1 , AD-64386 claim 1 , AD-64387 claim 1 , AD-64389 claim 1 , AD-64601 claim 1 , AD-64569 claim 1 , AD-64604 claim 1 , AD-64567 claim 1 , AD-60940 claim 1 , AD-64601 claim 1 , AD-65105 claim 1 , AD-65106 claim 1 , AD-65107 claim 1 , AD-65108 claim 1 , AD-65109 claim 1 , AD-65110 claim 1 , AD-65111 claim 1 , AD-65112 claim 1 , AD-61002 claim 1 , AD-66014 claim 1 , AD-66015 claim 1 , and AD-65189.35.-. (canceled)6. The double stranded RNAi agent of claim 1 , further comprising a ligand.7. The double stranded RNAi agent of claim 6 , wherein the ligand is one or more GalNAc derivatives attached through a bivalent or trivalent branched linker.9. The double stranded RNAi agent of claim 6 , wherein the ligand is attached to the 3′ end of the sense strand.11. (canceled)12. (canceled)13. A pharmaceutical composition comprising the double stranded ...

Reusable minimally invasive surgical instrument

A reusable tip for minimally invasive surgical instruments can include an end effector, a two-part hub, and a yoke. The end effector can include one or more movable portions enabling the end effector to move between first (e.g., open) and second (e.g., closed) positions via manipulation of the yoke within the hub. The hub can include a proximal hub and a distal hub coupled together. The end effector can be coupled to the distal hub, which can be made of a metal to provide high strength and secure shape to the distal hub. The proximal hub can be made of an autoclavable insulation material capable of maintaining a removable coupling with a control shaft. The proximal hub can be made of polyetheretherketone (PEEK).

ANGIOTENSINOGEN (AGT) iRNA COMPOSITIONS AND METHODS OF USE THEREOF

The present invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the angiotensinogen (AGT) gene, and methods of using such RNAi agents to inhibit expression of AGT and methods of treating subjects having an AGT-associated disorder, e.g., hypertension. 1. (canceled)2. A double-stranded ribonucleic acid (RNAi) agent for inhibiting expression of angiotensinogen (AGT) in a cell , wherein said double-stranded RNAi agent comprises a sense strand and an antisense strand forming a double-stranded region ,wherein the sense strand comprises at least 15 contiguous nucleotides of nucleotides 803-843; 834-859; 803-859; 803-875; 834-875; 847-875; 1247-1271; 1566-1624; 1570-1624; 1584-1624; 1584-1624; 1584-1621; 2035-2144; 2070-2144; 2070-2103; 2201-2223; 2227-2360; 2227-2304; 2290-2318; 2304-2350; 2304-2326; 2320-2342; 2333-2360; 2333-2358; 485-503; 517-535; 560-578; 635-653; 803-821; 814-832; 822-840; 825-843; 834-852; 837-855; 841-859; 855-873; 967-985; 1247-1265; 1248-1266; 1249-1267; 1251-1269; 1253-1271; 1566-1584; 1570-1588; 1572-1590; 1574-1592; 1584-1602; 1587-1605; 1591-1609; 1592-1610; 1595-1613; 1601-1619; 1602-1620; 1605-1623; 1729-1747; 1738-1756; 1739-1757; 1741-1769; 1767-1785; 1810-1828; 1827-1845; 1880-1989; 1892-1914; 1894-1914; 1894-2012; 2035-2053; 2046-2064; 2057-2075; 2070-2088; 2072-2090; 2078-2096; 2078-2107; 2078-2011; 2080-2098; 2081-2099; 2081-2104; 2081-2011; 2082-2100; 2084-2102; 2084-2011; 2090-2108; 2100-2118; 2111-2129; 2124-2142; 2125-2143; 2167-2185; 2179-2197; 2201-2219; 2202-2220; 2203-2221; 2204-2222; 2227-2245; 2230-2248; 2234-2252; 2244-2264; 2255-2273; 2266-2284; 2268-2286; 2270-2288; 2279-2297; 2281-2299; 2283-2301; 2284-2302; 2285-2303; 2286-2304; 2288-2306; 2290-2308; 2291-2309; 2291-2311; 2291-2318; 2291-2315; 2292-2310; 2294-2312; 2296-2314; 2299-2317; 2304-2322; 2304-2329; 2306-2324; 2307-2325; 2309-2327; 2309-2329; 2309-2342; 2309-2350; 2309-2358; 2314-2332; 2316-2334; 2317-2335; 2320-2338; 2321-2339; 2323- ...

SERPINA1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF

The invention relates to RNAi agents, e.g., double stranded RNAi agents, targeting the Serpina1 gene, and methods of using such RNAi agents to inhibit expression of Serpina1 and methods of treating subjects having a Serpina1 associated disease, such as a liver disorder. 1. A double stranded RNA (dsRNA) agent that inhibits expression of a serine peptidase inhibitor , clade A , member 1 (Serpina1) gene , comprising a sense strand and an antisense strand forming a double stranded region , said antisense strand comprising a region of complementarity to an mRNA encoding Serpina1 , wherein the region of complementarity comprises at least 15 contiguous nucleotides differing by no more than 3 nucleotides from the nucleotide sequence of SEQ ID NO:15 ,wherein said antisense strand comprises at least one thermally destabilizing modification within the first 9 nucleotide positions of the 5′ region or a precursor thereof,wherein said sense strand comprises an ASGPR ligand,wherein each of the sense strand and the antisense strand are independently 14 to 40 nucleotides in length.3. The dsRNA agent according to claim 1 , wherein the antisense strand has at least two of the following characteristics:a) the thermally destabilizing modification is located in position 4 to 8 of the antisense strand;b) at least two nucleotides comprise a 2′-fluoro modification;c) a phosphorothioate internucleotide linkage between nucleotide positions 1 and 2 (counting from the 5′ end);d) a length of 18 to 35 nucleotides.4. The dsRNA agent according to claim 1 , having at least one of the following characteristics:a) the ASGPR ligand attached to either end of the sense strand;b) at least two nucleotides comprise a 2′-fluoro modification;c) the double stranded region spans at least 19 nucleotide positions and wherein the thermally destabilizing modification is located within said double stranded region.6. The dsRNA agent according to claim 1 , wherein the ASGPR ligand is one or more GalNAc derivatives ...

TMPRSS6 iRNA COMPOSITIONS AND METHODS OF USE THEREOF

The invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the TMPRSS6 gene, and methods of using such RNAi agents to inhibit expression of TMPRSS6 and methods of treating subjects having a TMPRSS6 associated disorder, e.g., an iron overload associated disorder, such as β-thalassemia or hemochromatosis. 1. A double stranded RNAi agent for inhibiting expression of TMPRSS6 in a cell , wherein said double stranded RNAi agent comprises a sense strand and an antisense strand forming a duplex , wherein the sense strand and the antisense strand comprise the sense and antisense strand nucleotide sequences of any one of the duplexes provided in any one of Tables 6 , 7 , and 8.2. The double stranded RNAi agent of claim 1 , wherein the sense strand and the antisense strand comprise the sense and antisense strand nucleotide sequences of a duplex selected from the group consisting of AD-63202 claim 1 , AD-64372 claim 1 , AD-64373 claim 1 , AD-64374 claim 1 , AD-64375 claim 1 , AD-64376 claim 1 , AD-64377 claim 1 , AD-64378 claim 1 , AD-64380 claim 1 , AD-64381 claim 1 , AD-64382 claim 1 , AD-64384 claim 1 , AD-64385 claim 1 , AD-64386 claim 1 , AD-64387 claim 1 , AD-64389 claim 1 , AD-64601 claim 1 , AD-64569 claim 1 , AD-64604 claim 1 , AD-64567 claim 1 , AD-60940 claim 1 , AD-64601 claim 1 , AD-65105 claim 1 , AD-65106 claim 1 , AD-65107 claim 1 , AD-65108 claim 1 , AD-65109 claim 1 , AD-65110 claim 1 , AD-65111 claim 1 , AD-65112 claim 1 , AD-61002 claim 1 , AD-66014 claim 1 , AD-66015 claim 1 , and AD-65189.35.-. (canceled)6. The double stranded RNAi agent of claim 1 , further comprising a ligand.7. The double stranded RNAi agent of claim 6 , wherein the ligand is one or more GalNAc derivatives attached through a bivalent or trivalent branched linker.9. The double stranded RNAi agent of claim 6 , wherein the ligand is attached to the 3′ end of the sense strand.11. (canceled)12. (canceled)13. A pharmaceutical composition comprising the double stranded ...

Collapsible playard

A system includes a support frame of a foldable playard, bassinet fabrics attached to the support frame of the playard, and a hub system attached to the support frame and

Collapsible playard

A playard includes a collapsible frame having scissoring members vertically extending and forming sides, the frame lacking horizontal top members, a removable fabric enclosure, the removable fabric enclosure including a removable top portion, and a removable bottom portion, the removable top portion secured to an upper portion of the collapsible frame with an attachment device configured to removably engage corresponding receptacles in the upper collapsible frame.

Rapid-exchange system and method

A connector for placing an elongate endovascular device and an electrical accessory item into electrical connection is described. A connector body with longitudinally separated proximal and distal body ends is electrically connected to the electrical accessory item. A connection cavity extends into, and partially through, the connector body from a cavity aperture in the distal body end. At least one electrical connector contact is located in the connection cavity. The electrical connector contact is configured for longitudinal alignment with, and electrical communication to, at least a conductive portion of the endovascular device selectively present in the connection cavity. A device grasper is operable to selectively maintain the conductive portion of the endovascular device longitudinally within the connection cavity. A method and system for using the connector are also disclosed.

Lateral flow assay and device using magnetic particles

A complex including magnetic particle bound to a metal colloid. The complex may be part of a reagent for use in a method for determining analytes. The reagent may include a binding partner specific for an analyte. The reagent may further include a first label that is distinguishable from a second label that is used to detect the analyte. The reagent is used in kits and methods for detecting analytes in samples. The methods include immunoassay methods, including method where the first label is used to calibrate the assay.

Lateral flow assay and device using magnetic particles

A complex including magnetic particle bound to a metal colloid. The complex may be part of a reagent for use in a method for determining analytes. The reagent may include a binding partner specific for an analyte. The reagent may further include a first label that is distinguishable from a second label that is used to detect the analyte. The reagent is used in kits and methods for detecting analytes in samples. The methods include immunoassay methods, including method where the first label is used to calibrate the assay.

Surgical tool systems and methods

Embodiments of the present disclosure provide a surgical robot system may include an end-effector element configured for controlled movement and positioning and tracking of surgical instruments and objects relative to an image of a patient's anatomical structure. In some embodiments the end-effector may be tracked by surgical robot system and displayed to a user. In some embodiments the end-effector element may be configured to restrict the movement of an instrument assembly in a guide tube. In some embodiments, the end-effector may contain structures to allow for magnetic coupling to a robot arm and/or wireless powering of the end-effector element. In some embodiments, tracking of a target anatomical structure and objects, both in a navigation space and an image space, may be provided by a dynamic reference base located at a position away from the target anatomical structure.

Disposable ophthalmic injection device

A disposable injection device has a dispensing chamber housing, a plunger, a needle, and a temperature control device. The dispensing chamber housing has an inner surface and an outer surface. The inner surface partially defines a dispensing chamber for receiving a quantity of a substance. The plunger is engaged with the inner surface of the dispensing chamber housing, is capable of sliding in the dispensing chamber housing, and is fluidly sealed to the inner surface of the dispensing chamber housing. The plunger has a plunger interface. The needle is fluidly coupled to the dispensing chamber. The temperature control device at least partially surrounds the dispensing chamber housing and alters a temperature of the substance in the dispensing chamber. The substance is injected after the temperature of the substance is altered.

Ophthalmic injection system

An ophthalmic injection system has a tip segment attachable to and removable from a limited reuse assembly. The tip segment has a dispensing chamber housing, a plunger, a needle, a temperature control device, a thermal sensor, and a first housing at least partially enclosing the dispensing chamber housing, the temperature control device and the plunger. The limited reuse assembly has an actuator with a shaft, a power source for providing power to the actuator, a controller for controlling the actuator, a mechanical linkage interface, and a second housing at least partially enclosing the power source, the controller, and the actuator. The mechanical linkage interface is coupled to the actuator shaft and has a mating surface on one end. The substance is injected after the temperature of the substance is altered.

Apparatus for sensing the flow of a substance through a liquid medium

Laminate film-foam flooring composition

A laminate composition of a thin film of low density polyethylene adhered to a sheet of low density polyethylene foam by means of a very thin layer of low density polyethylene. The polyethylene foam has a low density which is preferably between about 1.9 pcf and about 2.2 pcf. The bottom polyethylene film serves as a vapor barrier. One side of the polyethylene film extends beyond one edge of the polyethylene foam sheet. The laminate composition is installed in a free floating manner on the concrete subflooring, with the polyethylene film or the polyethylene foam sheet contacting the surface of the concrete subflooring. The laminate composition is usually in long strips, so when it is installed one edge of one strip overlies the extended portion of the polyethylene film of an adjacent strip. Tape having adhesive on both sides can be positioned between the overlay region to adhere together the overlaid portions to prevent movement thereof during installation of the laminate wood finish flooring. Then the laminate wood finish flooring, in plank form, is installed on top of the laminate composition in a free floating manner. The laminate wood planks fit together in a tongue-in-groove manner and are glued together.

Compositions and methods for removing soils from surfaces

The present invention relates to a an aqueous composition for removing soils from a surface to be cleaned, formed from water, a detergent mixture and a rinse aid, wherein the detergent mixture comprises a peroxidation catalyst and wherein the rinse aid comprises an oxygen source. Such a composition may provide a more effective cleaning behaviour. The present invention further relates to a method for removing soil from a surface to be cleaned comprising applying to the surface to be cleaned a composition according to the invention.

Wind turbines

A rotor is mounted in a channel formed across the apex of a pitched roof. The rotor is movable about a vertical axis so as to face a prevailing wind direction. The rotor is arranged so as to face down the pitch of the roof, and a portion of the rotor extends below the apex of the roof, as this has been found to improve power generation. In another embodiment (Figure 1), the rotor is mounted between tapered wind channels for directing air towards the rotor.

Wind turbines

A rotor is mounted in a channel formed across the apex of a pitched roof. The rotor is movable about a vertical axis so as to face a prevailing wind direction. The rotor is arranged so as to face down the pitch of the roof, and a portion of the rotor extends below the apex of the roof, as this has been found to improve power generation. In another embodiment (Figure 1), the rotor is mounted between tapered wind channels for directing air towards the rotor.

HUMAN C-FMS ANTI-BINDING PROTEINS

Human c-fms antigen binding proteins

Antigen binding proteins that bind to human c-fms protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of c-fms to CSF-I, reduce monocyte migration into tumors, and reduce the accumulation of tumor-associated macrophages.

Human c-fms antigen binding proteins

Antigen binding proteins that bind to human c-fms protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of c-fms to CSF-I, reduce monocyte migration into tumors, and reduce the accumulation of tumor-associated macrophages.

Human c-fms antigen binding proteins

Antigen binding proteins that bind to human c-fms protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of c-fms to CSF-I, reduce monocyte migration into tumors, and reduce the accumulation of tumor-associated macrophages.

Metal working drill/endmill blank and its method of manufacture

A cemented carbide drill/endmill blank and method of manufacture thereof wherein the drill/endmill includes a core and a surrounding tube with improved technological properties. The difference in Co-content between the core and tube is 1-10 wt-% units and the cubic carbide content is 8-20 wt-% in the tube and 0.5-2 wt-% in the core.

Systems and methods for containing biological samples

An article for holding a plurality of biological samples includes a substrate a substrate comprising a first surface and an opposing second surface and a plurality of reaction sites in the substrate. Each of the reaction sites extends from an opening in the first surface to an opening in the second surface. The reaction sites comprise a hexagonal shape and are configured to provide sufficient surface tension by capillary action to hold respective biological samples. The reaction sites have a density over at least a portion of the surfaces that is at least 170 holes per square millimeter. At least one of the surfaces may have a surface roughness characterized by an arithmetic average roughness (Ra) that is less than or equal to 5 nanometers.

BUOYANT PLATFORM

A buoyant offshore renewable energy system mounting platform is provided for positioning a renewable energy device in a body of water, the body of water comprising a surface and a bed, the platform comprising a framework, comprising at least three vertexes, and at least one mooring member for positioning the platform relative to the surface and bed of the body of water. Each of the at least three vertexes having at least one buoyancy member. The buoyancy member preferably comprising a plurality of buoyancy units wherein at least one of the buoyancy members comprises a renewable energy device selected from: a renewable energy convertor; a renewable energy harnessing apparatus; a renewable energy processing apparatus; a renewable energy storing apparatus; a renewable energy data capture apparatus; a data storing apparatus.

Compositions and methods for removing soils from surfaces

The present invention relates to a an aqueous composition for removing soils from a surface to be cleaned, formed from water, a detergent mixture and a rinse aid, wherein the detergent mixture comprises a peroxidation catalyst and wherein the rinse aid comprises an oxygen source. Such a composition may provide a more effective cleaning behaviour. The present invention further relates to a method for removing soil from a surface to be cleaned comprising applying to the surface to be cleaned a composition according to the invention.

POLYPEPTIDFOERENINGAR SOM HAR VAEXTHORMON FRIGOERANDE VERKAN

AIRCRAFT TURBOMACHINE CRANKCASE AND METHOD FOR MANUFACTURING THEREOF

Carter (3) de turbomachine d’aéronef, ce carter comportant : - une enveloppe annulaire (9) s’étendant autour d’un axe A et réalisée dans un matériau composite comportant des fibres tissées et noyées dans une résine, - une couche annulaire (4) en matériau abradable s’étendant à l’intérieur de l’enveloppe, autour de l’axe A, et obtenue par étalement et polymérisation d’une pâte, et - des panneaux supports (10) s’étendant autour de l’axe A et intercalés entre l’enveloppe et la couche abradable. Figure pour l'abrégé : Figure 10

Clamp arm features for ultrasonic surgical instrument.

Un aparato quirúrgico incluye un efector de extremo que tiene una cuchilla ultrasónica, un brazo de sujeción y una almohadilla de sujeción; el efector de extremo aplica energía ultrasónica en la cuchilla; el brazo de sujeción gira con respecto a la cuchilla; la almohadilla de sujeción se coloca en el brazo de sujeción adyacente a la cuchilla; el brazo de sujeción incluye una característica de trabado para retener la almohadilla de sujeción en relación con el brazo de sujeción a fin de evitar que la almohadilla de sujeción se desplace lateralmente, longitudinalmente y perpendicularmente con respecto al brazo de sujeción.

Concentrated detergent composition for the improved removal of starch in warewashing applications

The invention provides a concentrated detergent composition alkali metal carbonate, alkali metal percarbonate, and a peroxidation catalyst according to formula (I) wherein each L independently is an organic ligand containing at least three nitrogen atoms that coordinate with the metal M; M is Mn or Fe; each X independently is a coordinating or bridging group selected from the group consisting of H2O, OH-, SH-, H02-, O2-, O22-, S2-, F-, CI-, Br-, I-, NO3 -, NO2 -, formula (II), SO4 2-, SO3 2-, PO4 3-, N3-, CN-, NR3, NCS-, RCN, RS-, RCO2 -, RO-, and with R being hydrogen or a C1 to C6 alkyl group; p is an integer from 1 to 4; q is an integer from 1 to 2; r is an integer from 0 to 6; Y is a counter ion; and s is the number of counter ions. The invention also relates to the use of said concentrated detergent composition as a warewashing detergent for the removal of starch soil.

Onboard heater of auxiliary systems using exhaust gases and associated methods

An exhaust energy recovery system (EERS) and associated methods for an engine are disclosed. An embodiment of an EERS, for example, includes an inlet duct that is configured to divert exhaust gas from an exhaust duct of the engine into the recovery system and an outlet duct configured to return the exhaust gas to the exhaust duct downstream of the inlet duct. The recovery system is configured to heat components or fluids associated with engine to operating temperatures. The recovery system may be part of a mobile power system that is mounted to a single trailer and includes an engine and a power unit such as a high pressure pump or generator mounted to the trailer. Methods of operating and purging recovery systems are also disclosed.

Surgical tool systems and methods

Embodiments of the present disclosure provide a surgical robot system may include an end-effector element configured for controlled movement and positioning and tracking of surgical instruments and objects relative to an image of a patient's anatomical structure. In some embodiments the end-effector may be tracked by surgical robot system and displayed to a user. In some embodiments the end-effector element may be configured to restrict the movement of an instrument assembly in a guide tube. In some embodiments, the end-effector may contain structures to allow for magnetic coupling to a robot arm and/or wireless powering of the end-effector element. In some embodiments, tracking of a target anatomical structure and objects, both in a navigation space and an image space, may be provided by a dynamic reference base located at a position away from the target anatomical structure.

Devices and techniques for cutting and coagulating tissue.

Se dirigen varias formas a sistemas y métodos para el accionamiento de un efector de extremo acoplado a un sistema de accionamiento ultrasónico de un instrumento quirúrgico; un generador puede generar al menos una señal eléctrica puede monitorearse contra un primer conjunto de condiciones lógicas; cuando una impedancia ultrasónica del instrumento quirúrgico supera un umbral de impedancia, una frecuencia de resonancia de la al menos una señal eléctrica puede almacenarse como una frecuencia de línea base; una primera respuesta del generador puede activarse ante la ocurrencia de ya sea que el primer conjunto de condiciones lógicas se cumpla o la frecuencia de resonancia de la al menos una señal eléctrica difiera de la frecuencia de línea base por un umbral de desviación de línea base.

Synergistic protein soil removal through novel chelator combination

The invention relates to a concentrated detergent composition comprising surfactant, alkali metal carbonate, methylglycinediacetic acid, glutamic acid N,N-diacetic acid, and alkali metal tripolyphosphate. The composition is particularly suited to remove protein soil in warewashing applications.

Intelligent call processing platform for home telephone system

The present invention comprises an intelligent call processing platform (2) for use with a home telephone system (4a-4n). The system consists of a processing unit interfaced with a variety of memory storage areas, a central office providing local telephone service and a plurality of telephone handsets (4a-4n). Using a variety of voice and/or pushbutton commands, a user is able to access a variety of telephone services from any telephone interfaced with the platform (2). Services provided include: identification of incoming callers, automatic speed dialing of user-stored telephone numbers, storage of new numbers to the user-stored list of telephone numbers and control of peripheral systems interconnected with the intelligent call processing platform (2).

Burner and method of burning gas in a furnace

A gas burner for use in a furnace and a method of burning gas in a furnace, especially but not exclusively a process furnace used in an oil cracking or refining process. The gas burner comprises two passageways with adjacent outlets. The first passage way is in fluid communication with a source of pressurised fuel gas and has an aperture through which recirculated flue gas can enter the first passageway and the second passageway is in fluid communication with a source of air. In operation, fuel gas is injected into the first passageway and recirculated flue gas is thereby drawn into the first passageway so that it mixes with the fuel gas. Fuel gas is partially combusted and a mixture of partially combusted fuel gas and recirculated flue gas flows up the first passageway and comes into contact with air from the second passageway and combusts. The use of recirculated flue gas keeps down the level of NOx emissions and as the recirculated flue gas is sucked into the first passageway by the pressurised fuel gas flow it is not necessary to provide complex pumping mechanisms.

Ultrasonic surgical blade and instrument having a gain step

An ultrasonic surgical blade, and an instrument, having a gain step. The blade body has, in any half wave length of the ultrasonic-surgical-blade body, a first vibration antinode, a vibration node, a second vibration antinode, and a gain step. The gain step is located between the second vibration antinode and the first vibration antinode. The gain step is spaced apart from the vibration node by a gain-step distance greater than 5% of the distance between the second vibration antinode and the first vibration antinode. The instrument includes the blade, a handpiece having an ultrasonic transducer, and an ultrasonic transmission rod whose proximal end is operatively connected to the ultrasonic transducer and whose distal end activates the blade. In one option, the first vibration antinode is the distal tip, and the gain step is located between the vibration node and the distal tip, resulting in an increased active length of the blade.

Reusable minimally invasive surgical instrument

A reusable tip for minimally invasive surgical instruments can include an end effector, a two-part hub, and a yoke. The end effector can include one or more movable portions enabling the end effector to move between first (e.g., open) and second (e.g., closed) positions via manipulation of the yoke within the hub. The hub can include a proximal hub and a distal hub coupled together. The end effector can be coupled to the distal hub, which can be made of a metal to provide high strength and secure shape to the distal hub. The proximal hub can be made of an autoclavable insulation material capable of maintaining a removable coupling with a control shaft. The proximal hub can be made of polyetheretherketone (PEEK).

Systems and method for biological analysis

A system for processing a plurality of biological samples contains a support and a temperature controller. The support is configured to hold a case that includes an inner chamber and a substrate located within the inner chamber, the substrate containing a plurality of isolated reaction sites containing one or more biological samples. The temperature controller is configured to maintain or control a temperature of at least one of the support, the case, or the one or more biological samples during an assay or reaction on the one or more biological samples. The support is also configured to maintain at least one of the surfaces of substrate at a positive angle relative to a horizontal plane during the assay or reaction.

Compositions and methods for removing soils from surfaces

The present invention relates to a an aqueous composition for removing soils from a surface to be cleaned, formed from water, a detergent mixture and a rinse aid, wherein the detergent mixture comprises a peroxidation catalyst and wherein the rinse aid comprises an oxygen source. Such a composition may provide a more effective cleaning behaviour. The present invention further relates to a method for removing soil from a surface to be cleaned comprising applying to the surface to be cleaned a composition according to the invention.

Method and system to facilitate intraoperative positioning and guidance

System and methods are disclosed to facilitate intra-operative procedures and planning. A method can include storing tracking data in memory, the tracking data being generated (502) by a tracking system to represent a location of an object in a tracking coordinate system of the tracking system. The method can also include storing a patient-specific implicit model in memory, the patient-specific implicit model being generated (504) based on image data acquired for the patient to define geometry of an anatomical structure of the patient. The method can also include registering the tracking data and the patient-specific implicit model (506) in a common three-dimensional coordinate system. The method can also include generating an output visualization (508) representing a location of the object relative to the geometry of the anatomical structure of the patient in the common coordinate system.

Trail receptor 2 polypeptides and antibodies

Polypeptides are provided. Antibodies or antigen binding domains are provided which bind such polypeptides. Also provided are methods of obtaining an antibody that binds tumor necrosis factor (TNF)-related apoptosis-inducing ligand ('TRAIL') Receptor-2 (TR-2) comprising administering at least one of such polypeptides to an animal and obtaining an antibody that binds TR-2 from the animal. Antibodies reactive with TR-2 are provided. Also provided are cells producing antibodies reactive with TR-2, pharmaceutical compositions comprising antibodies reactive with TR-2, methods using antibodies reactive with TR-2, and kits comprising antibodies reactive with TR-2. Also provided are methods of decreasing or preventing binding of an antibody to TR-2 by administering such a polypeptide.

Systems and methods to enhance intake air flow to a gas turbine engine of a hydraulic fracturing unit

Systems and methods to increase intake air flow to a gas turbine engine of a hydraulic fracturing unit when positioned in an enclosure may include providing an intake expansion assembly to enhance intake air flow to the gas turbine engine. The intake expansion assembly may include an intake expansion wall defining a plurality of intake ports positioned to supply intake air to the gas turbine engine. The intake expansion assembly also may include one or more actuators connected to a main housing of the enclosure and the intake expansion assembly. The one or more actuators may be positioned to cause the intake expansion wall to move relative to the main housing between a first position preventing air flow through the plurality of intake ports and a second position providing air flow through the plurality of intake ports to an interior of the enclosure.

Climate control

Traverse mechanism for winding-machines, &c.

Sample processing

A sample processing system for use with analysis apparatus includes tubular structure that defines a continuous elongated flow chamber. The tubular structure has an inlet port at one end, an outlet port at the other end, and a sample inlet port in communication with the continuous elongated flow chamber between the inlet and outlet ports. A first pump flows diluent at a first rate through the inlet port for flow through the continuous elongated flow chamber, and a second pump flows a liquid mixture from the continuous elongated flow chamber through the outlet port at a rate greater than the first rate. With the sample inlet port submerged in a sample to be analyzed, the sample is aspirated through the sample inlet port into the flowing diluent stream in the continuous elongated flow chamber for dilution and application of the diluted sample mixture to sample analysis apparatus for analysis.

Polypeptides and Antibodies

Polypeptides are provided. Antibodies or antigen binding domains are provided which bind such polypeptides. Also provided are methods of obtaining an antibody that binds tumor necrosis factor (TNF)-related apoptosis-inducing ligand (“TRAIL”) Receptor-2 (TR-2) comprising administering at least one of such polypeptides to an animal and obtaining an antibody that binds TR-2 from the animal. Antibodies reactive with TR-2 are provided. Also provided are cells producing antibodies reactive with TR-2, pharmaceutical compositions comprising antibodies reactive with TR-2, methods using antibodies reactive with TR-2, and kits comprising antibodies reactive with TR-2. Also provided are methods of decreasing or preventing binding of an antibody to TR-2 by administering such a polypeptide.

Inorganic intumescent fire protective coatings

The invention disclosed is a fire resistant inorganic coating composition which intumesces when subject to high temperatures to form a substantially continuous heat insulating structure and retains this structure for prolonged periods at temperatures up to 1000° C. The coating composition comprises ______________________________________ Parts by Weight ______________________________________ sodium silicate (aqueous solution) 40-70 potassium silicate (aqueous solution) 40-70 silicon carbide powder 3-15 ______________________________________ A composite fire-protective coating system is also disclosed which comprises a plurality of coatings sequentially applied to the substrate, typically aluminum, to be protected. Specifically, a first heat resistant, substantially air impermeable bonding layer and an inorganic intumescent layer as described above. An additional heat resistant air impermeable layer may be included as a top coat. Some applications may require an additional inorganic intumescent layer.

Methods for liquefied natural gas fueling

A method and apparatus for fueling the onboard storage tank of a vehicle with liquefied natural gas. A liquid cryogen such as liquid nitrogen is fed to a condensing unit to condense natural gas present in a fueling system. Liquefied natural gas is fed into the fueling system and natural gas vapor is recovered from the onboard storage tank of the vehicle and fed to the condensing unit. When the pressure of the onboard storage tanks is sufficient, the liquefied natural gas is fed from the fueling system to the onboard storage tanks. C aT AA CN iRgu C Figure 1

Complement component c5 irna compositions and methods of use thereof.

La presente invención se refiere a ARNi, por ejemplo, composiciones de ácido ribonucleico de hebra doble (ARNhd), dirigidas al gen del componente C5 del complemento, y métodos para usar el ARNi, por ejemplo, ARNhd, composiciones para inhibir la expresión de C5 y para tratar sujetos que tienen una enfermedad asociada con el componente C5 del complemento, por ejemplo, hemoglobinuria paroxística nocturna.

Method of connecting modules of an endoluminal prosthesis

Branched vessel endoluminal device

An endoluminal prosthesis comprises a prosthetic trunk comprising a trunk lumen extending therethrough, a wall, and an anastomosis in the wall, wherein the prosthetic trunk has a circumference. The endoluminal prosthesis further comprises a prosthetic branch comprising a branch lumen extending therethrough. The branch lumen is in fluid communication with the trunk lumen through the anastomosis. The prosthetic branch is disposed longitudinally along and circumferentially about the prosthetic trunk.

Methods for detection and mitigation of well screen out

Methods, systems, and controllers for detecting and mitigating well screen outs may include a controller configured to operate a fracturing pump to supply fluid at a discharge rate to a wellhead at a fracturing well site. The controller may also operate a blender positioned to deliver a blend of proppant and fluid to the fracturing pump. The controller may compare a fluid pressure increase rate to a preselected increase rate indicative of a potential well screen out. The controller may incrementally decrease the discharge rate of the fracturing pump and a flow rate of a blender when the fluid pressure increase rate of the wellhead exceeds the preselected increase rate and the fluid pressure is within a preselected percentage of a maximum wellhead pressure until the fluid pressure of the fluid supplied to the wellhead is stabilized.

Valve

Mooring arrangement for a tension leg platform

A buoyant tension leg platform 102 is provided, the platform being arranged to support a renewable energy capturing device 104 when the platform is submerged in a body of water. The platform comprises at least three vertices 106, at least three of said vertices having a mooring arrangement 108. The mooring arrangement comprises a first mooring line 110 extending between said vertex and a first anchor point 112 in communication with a bed of said body of water, the first mooring line extending at an angle relative to said bed and a second mooring line 114 extending from the first vertex to a second said anchor point 116, the second mooring line extending at the angle relative to said bed, such that each said mooring arrangement of a corresponding vertex defines a triangle 118 positioned on a plane. The present disclosure aims to provide improved stability of such platforms when submerged and supporting a renewable energy capturing device.

Underground infrastructure sensing using unmanned aerial vehicle (UAV)

One aspect provides a method, including: obtaining sensor data from an unmanned aerial vehicle (UAV); the sensor data comprising data obtained by one or more sensors of the UAV; analyzing, using a processor, the sensor data to detect underground water associated with a pipe; and identifying, with the processor, an underground feature based on the analyzing. Other aspects are described and claimed.

HIV integrase inhibitors

Process and apparatus for improved methods for making vinyl acetate monomer (vam)

Human c-fms antigen binding proteins.

Se proporcionan proteínas enlazadas al antígeno que enlazan a proteína c-fms humana. Se proporcionan también ácidos nucleicos que codifican la proteína enlazada al antígeno, vectores, y células que codifican el mismo. Las proteínas enlazadas al antígeno pueden inhibir el enlace de c-fms a CSF-I, reduce migración de monocito en tumores, y reduce la acumulación de macrófagos asociados a tumor.

High frequency and high frequency frame ultrasound imaging system

Un sistema (100) para desarrollar una imagen por uUn sistema (100) para desarrollar una imagen por ultrasonidos, que comprende: una cabeza de barrido ltrasonidos, que comprende: una cabeza de barrido que tiene un transductor (8) con capacidad para geque tiene un transductor (8) con capacidad para generar energía de ultrasonidos auna frecuencia de anerar energía de ultrasonidos auna frecuencia de al menos 20 megahercios (MHz), en el que dicho tranl menos 20 megahercios (MHz), en el que dicho transductor (8) está encapsulado en elinterior de un vsductor (8) está encapsulado en elinterior de un volumen cerrado que está definido parcialmente por olumen cerrado que está definido parcialmente por una ventana acústica (125) posicionableentre el truna ventana acústica (125) posicionableentre el transductor y un sujeto (108); un motor de par confiansductor y un sujeto (108); un motor de par configurado para hacer oscilar el transductor en el intgurado para hacer oscilar el transductor en el interior del volumen cerrado a lo largode un recorriderior del volumen cerrado a lo largode un recorrido arqueado convexo oscilante a una frecuencia de ao arqueado convexo oscilante a una frecuencia de al menos 7,5 Hz, en el que el transductorestá confil menos 7,5 Hz, en el que el transductorestá configurado para transmitir energía de ultrasonidos a tgurado para transmitir energía de ultrasonidos a través de la ventana acústica al interior del sujetravés de la ventana acústica al interior del sujetoy recibir ecos ultrasónicos del sujeto a través doy recibir ecos ultrasónicos del sujeto a través de la ventana acústica; un codificador (128) de la e la ventana acústica; un codificador (128) de la posición configurado para determinar la posición eposición configurado para determinar la posición espacial del transductor (8) a lolargo del recorridspacial del transductor (8) a lolargo del recorrido arqueado convexo oscilante con una precisión de o arqueado convexo oscilante con una precisión de ...

PEPTIDE, PROCESS TO PROMOTE THE RELEASE OF GROWTH HORMONE LEVELS IN ANIMAL, PHARMACEUTICAL COMPOSITION TO PROMOTE THE RELEASE OF GROWTH HORMONE LEVELS IN ANIMALS, USE OF THE COMPOUND AND PROCESS TO PROMOTE THE LIBERATION IN THE ELEVATION BLOOD

Golf putter head

Systems and methods to monitor, detect, and/or intervene relative to cavitation and pulsation events during a hydraulic fracturing operation

Systems and methods for monitoring, detecting, and/or intervening with respect to cavitation and pulsation events during hydraulic fracturing operations may include a supervisory controller. The supervisory controller may be configured to receive pump signals indicative of one or more of pump discharge pressure, pump suction pressure, pump speed, or pump vibration associated with operation of the hydraulic fracturing pump. The supervisory controller also may be configured to receive blender signals indicative of one or more of blender flow rate or blender discharge pressure. Based on one or more of these signals, the supervisory controller may be configured to detect a cavitation event and/or a pulsation event. The supervisory controller may be configured to generate a cavitation notification signal indicative of detection of cavitation associated with operation of the hydraulic fracturing pump, and/or a pulsation notification signal indicative of detection of pulsation associated with operation of the hydraulic fracturing pump.